PROGRAM

Speaker Profile

Time slot's time in Taipei (GMT+8)

President Award -2026/11/7

201 BCDE

20th Anniversary of Taiwan Movement Disorder Society The Journey of Dedication and Engagement: Where We Commence and What We Expand

  • Time
  • Topic
  • Speaker
  • Moderator
(Taiwan)
  • Chin-Song  Lu
  • MD
  • Superintendent of Professor Lu Neurological Clinic, Advisor of Landseed International Hospital
    E-mail:bob.cslu@gmail.com
Executive Summary:
Prof Chin-Song Lu is a Professor of Neurology serving as the Superintendent of Professor Lu Neurological Clinic, majoring in Parkinson’s disease and related movement disorders. Prof Lu is also serving as the Director of Landseed International Hospital. Prof Lu had previously served as the Chair of Neuroscience Research Centre, Chair of Department of Neurology and Chair of Division of Movement Disorders at Chang Gung Memorial Hospital, Linkou Medical Center. Among his numerous professional activities, he was the founder of Movement Disorders Group in Taiwan Neurological Society and promoter of Taiwan Movement Disorders Society. Prof Lu had served as the President of 19th Taiwan Neurological Society 2013. He is a member of Movement Disorder Society, American Academy of Neurology and International Association of Parkinson’s Disease and Related Disorders. Prof Lu's research interests cover many aspects of disorders of movement in neurology mainly including clinical drug trials, molecular and functional imaging and genetic research in Parkinson’s disease and other related movement disorders.
Lecture Abstract:
Over the past three decades, neuroimaging of Parkinsonian disorders in Taiwan has progressed from access to precision, and now toward pathology-specific diagnosis and artificial intelligence.
The launch began with 99mTc-TRODAT-1, the first technetium-labeled dopamine transporter (DAT) tracer. Through collaboration among Chang Gung Memorial Hospital, the Institute of Nuclear Energy Research, the University of Pennsylvania, and government agencies and industry, the tracer advanced from a phase I trial (1998) and a Taiwan invention patent (2001) to a phase III trial (2002), new-drug licensure (2005), and full National Health Insurance reimbursement (2010). It became Taiwan’s first reimbursed DAT imaging test, allowing same-day scanning without a cyclotron. Taiwanese cohorts established age-specific cutoffs that distinguished Parkinson’s disease (PD) from healthy controls with 100% sensitivity and specificity, detected dopaminergic loss in bilateral striata, majorly opposite to the clinically affected side, and extended its application to vascular parkinsonism, multiple system atrophy, and spinocerebellar ataxias, including asymptomatic Machado-Joseph disease carriers.
Innovation followed. 18F-FP-(+)-DTBZ PET, targeting vesicular monoamine transporter type 2, separated early PD from controls with 100% sensitivity and specificity in the posterior putamen and correlated with disease severity.
Recently, second-generation tau PET with 18F-florzolotau has shown increased subcortical binding in progressive supranuclear palsy, distinguished four-repeat tauopathies from controls (AUC 0.836), and correlated with plasma biomarkers.
Taiwan’s experience shows how local development, national insurance coverage, and sustained clinical research can turn an imaging innovation into routine care and a foundation for precision medicine.



Back